0001209191-22-015016.txt : 20220302
0001209191-22-015016.hdr.sgml : 20220302
20220302180452
ACCESSION NUMBER: 0001209191-22-015016
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220301
FILED AS OF DATE: 20220302
DATE AS OF CHANGE: 20220302
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: STOCKTON KEVIN A
CENTRAL INDEX KEY: 0001862464
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-15925
FILM NUMBER: 22705563
MAIL ADDRESS:
STREET 1: 4000 MERIDIAN BOULEVARD
CITY: FRANKLIN
STATE: TN
ZIP: 37067
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: COMMUNITY HEALTH SYSTEMS INC
CENTRAL INDEX KEY: 0001108109
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC [8062]
IRS NUMBER: 133893191
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4000 MERIDIAN BOULEVARD
CITY: FRANKLIN
STATE: TN
ZIP: 37067
BUSINESS PHONE: 615-465-7000
MAIL ADDRESS:
STREET 1: 4000 MERIDIAN BOULEVARD
CITY: FRANKLIN
STATE: TN
ZIP: 37067
FORMER COMPANY:
FORMER CONFORMED NAME: COMMUNITY HEALTH SYSTEMS INC/
DATE OF NAME CHANGE: 20000229
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-03-01
0
0001108109
COMMUNITY HEALTH SYSTEMS INC
CYH
0001862464
STOCKTON KEVIN A
4000 MERIDIAN BLVD
FRANKLIIN
TN
37067
0
1
0
0
Regional President
Common Stock
2022-03-01
4
A
0
25000
0.00
A
74984
D
Common Stock
2022-03-01
4
F
0
6350
10.18
D
68634
D
Performance Based Restricted
0.00
2022-03-01
4
A
0
50000
0.00
A
Common Stock
50000
50000
D
Stock Options (Right to Buy)
10.18
2022-03-01
4
A
0
25000
0.00
A
2023-03-01
2032-02-29
Common Stock
25000
25000
D
Performance Based Restricted
0.00
Common Stock
15000
15000
D
Performance Based Restricted
0.00
Common Stock
15000
15000
D
Stock Options (Right to Buy)
4.99
2020-03-01
2029-02-28
Common Stock
8000
8000
D
Stock Options (Right to Buy)
4.93
2021-03-01
2030-02-28
Common Stock
15000
15000
D
Stock Options (Right to Buy)
8.81
2022-03-01
2031-02-28
Common Stock
15000
15000
D
The time-vesting restrictions on this award of restricted stock will lapse in 1/3 increments on the first, second and third anniversary of the date of grant.
The vesting of these performance-based restricted shares is allocated to the attainment of the following pre-determined performance objectives between 1/1/2022 and 12/31/2024 (the "2022-2024 Performance Period"), as follows: 50% to a Cumulative Consolidated Adjusted EBITDA Growth target; and 50% to a Cumulative Same-Store Net Revenue Growth target. The target number (100%) of the total performance-based restricted shares is reported in the table set forth above. Between 0% and 200% of the portion of the target number of performance-based restricted shares allocated to each performance objective will ultimately vest on the third anniversary of the date of grant, subject to the attainment of the applicable performance objective, with the vesting percentage to be determined based upon the level of achievement with respect to the applicable performance objective during the 2022-2024 Performance Period.
Vesting occurs in 1/3 increments on the first, second and third anniversary of the date of grant.
The vesting of these performance-based restricted shares is subject to the attainment of certain performance objectives between 1/1/2020 and 12/31/2022 (the "2020-2022 Performance Period"). The target number (100%) of the total performance-based restricted shares is reported in the table set forth above. Between 0% and 200% of the portion of the target number of performance-based restricted shares allocated to each applicable performance objective will ultimately vest on the third anniversary of the date of grant, subject to the attainment of the applicable performance objective, with the vesting percentage to be determined based upon the level of achievement with respect to the applicable performance objective during the 2020-2022 Performance Period.
The vesting of these performance-based restricted shares is subject to the attainment of certain performance objectives between 1/1/2021 and 12/31/2023 (the "2021-2023 Performance Period"). The target number (100%) of the total performance-based restricted shares is reported in the table set forth above. Between 0% and 200% of the portion of the target number of performance-based restricted shares allocated to each applicable performance objective will ultimately vest on the third anniversary of the date of grant, subject to the attainment of the applicable performance objective, with the vesting percentage to be determined based upon the level of achievement with respect to the applicable performance objective during the 2021-2023 Performance Period.
Christopher G. Cobb, Attorney in Fact for Kevin A. Stockton
2022-03-02